title: [Effect of immunotherapy on the cellular immunity in patients with cervical cancer].
abstract: For the last thirty years immunotherapy has become an integral part of treatment of some cancers. The most effective approach in this context would be the use of complex immunostimulatory factors including tumor antigen in different forms, interleukins that stimulate differentiation.
  
  
  BACKGROUND
  The aim of the study was to compare cellular immune response on specific and combined immunotherapy in patients with cervical cancer.
  
  
  METHODS
  76 cervical cancer patients undergoing combined radiotherapy were included into the study. Plus to basic radiation treatment two types of immunotherapy was performed: first--autolymphocytes reinfusion after in vitro incubation with tumor antigen (tumor tissue homogenate) and interleukin-2, second--combination of above mentioned immunotherapy, interleukin-2 and systemic enzyme.
  
  
  RESULTS
  This has resulted in increase of cellular immunity parameters in the main group with combined immunotherapy an excess of cells with killer activity to ensure an effective antitumor immune response and, accordingly, the clinical efficacy of specific methods and adoptive immunotherapy in patients with cervical cancer.
  
  
  CONCLUSIONS
  Immunotherapy usage in the form of a preparation of interleukin-2 and a system enzymotherapy in a combination with a specific immunotherapy is possible. This way of treatment is recommended in cases of decreasing of cellular immunity indicators.
authors.forename: A F
authors.initials: AF
authors.lastname: Lazarev
authors.forename: D K
authors.initials: DK
authors.lastname: Kenbaeva
authors.forename: R K
authors.initials: RK
authors.lastname: Medeubaev
authors.forename: A E
authors.initials: AE
authors.lastname: Gorbatenko
authors.forename: S Z
authors.initials: SZ
authors.lastname: Tanatarov
mesh_terms: D000328:Adult; D000368:Aged; D000951:Antigens, Neoplasm / Q000276:immunology / Q000627:therapeutic use; D024221:Antineoplastic Protocols; D003888:Desensitization, Immunologic / Q000379:methods*; D057487:Enzyme Therapy / Q000379:methods*; D005260:Female; D006801:Humans; D007111:Immunity, Cellular / Q000276:immunology; D007376:Interleukin-2 / Q000276:immunology / Q000627:therapeutic use; D015166:Monitoring, Immunologic / Q000379:methods; D009367:Neoplasm Staging; D016896:Treatment Outcome; D002583:Uterine Cervical Neoplasms / Q000276:immunology / Q000473:pathology / Q000628:therapy
chemical_list: D000951:Antigens, Neoplasm; D007376:Interleukin-2